In previous studies we showed that a recombinant Modified Vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR-/-) against challenge. We continued these studies and determined, in the IFNAR-/- mouse model, whether the antibody responses induced by MVA-VP2 vaccination play a key role in protection against AHSV. Thus, groups of mice were vaccinated with wild type MVA (MVA-wt) or MVA-VP2 and the antisera from these mice were used in a passive immunisation experiment. Donor antisera from (a) MVA-wt; (b) MVA-VP2 vaccinated; or (c) MVA-VP2 vaccinated and AHSV infected mice, were transferred to AHSV non-immune recipient mice. The recipients were challenged with virulent AHSV together with MVA-VP2 vaccinated and MVA-wt vaccinated control animals and the levels of protection against AHSV-4 were compared between all these groups. The results showed that following AHSV challenge, mice that were passively immunised with MVA-VP2 vaccinated antisera were highly protected against AHSV disease and had lower levels of viraemia than recipients of MVA-wt antisera. Our study indicates that MVA-VP2 vaccination induces a highly protective humoral immune response against AHSV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.virusres.2013.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.
J Virol
December 2024
Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Valdeolmos, Madrid, Spain.
Article Synopsis
- Epizootic hemorrhagic disease (EHD) is a serious condition affecting livestock, caused by the emerging EHD virus, with recent outbreaks in Europe highlighting the urgent need for vaccine development.
- Researchers have developed two MVA-vectored vaccine candidates—one targeting protein VP2 of EHDV-8 and another targeting VP7 of EHDV-2—that show promise in protecting mice from EHD.
- The VP7 vaccine candidate is particularly noteworthy as it successfully protects against multiple EHDV strains without requiring neutralizing antibodies, marking it as a potential multiserotype vaccine solution in the fight against EHD.
Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.
Front Immunol
July 2024
Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC), Madrid, Spain.
Introduction: Bluetongue (BT), caused by bluetongue virus (BTV), is an important arthropod-borne livestock disease listed by the World Organization for Animal Health. Live-attenuated and inactivated vaccines have permitted to control BT but they do not simultaneously protect against the myriad of BTV serotypes. Recently, we identified the highly conserved BTV nonstructural protein NS1 and the N-terminal region of NS2 as antigens capable of conferring multiserotype protection against BTV.
View Article and Find Full Text PDFA single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
Vaccine
November 2018
Department of Biological & Medical Sciences, Oxford Brookes University, Oxford OX3 0BP, UK; The Pirbright Institute, Ash Road, Woking, Surrey GU24 0NB, UK; Department of Veterinary Medicine, University of Cambridge, Madingley Road, CB3 0ES Cambridge, UK. Electronic address:
African horse sickness is a severe, often fatal, arboviral disease of equids. The control of African horse sickness virus (AHSV) in endemic countries is based currently on the use of live attenuated vaccines despite some biosafety concerns derived from its biological properties. Thus, experimental vaccination platforms have been developed over the years in order to avoid the biosafety concerns associated with the use of attenuated vaccines.
View Article and Find Full Text PDFThe immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
Antiviral Res
June 2018
The Pirbright Institute, Ash Road, Pirbright, Surrey, GU24 0NF, UK. Electronic address:
African horse sickness (AHS) is a lethal equine disease transmitted by Culicoides biting midges and caused by African horse sickness virus (AHSV). AHS is endemic to sub-Saharan Africa, but devastating outbreaks have been recorded periodically outside this region. The perceived risk of an AHS outbreak occurring in Europe has increased following the frequent epidemics caused in ruminants by bluetongue virus, closely related to AHSV.
View Article and Find Full Text PDFVaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Vaccine
October 2017
The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, UK. Electronic address:
African horse sickness is a lethal viral disease of equids transmitted by biting midges of the Genus Culicoides. The disease is endemic to sub-Saharan Africa but outbreaks of high mortality and economic impact have occurred in the past in non-endemic regions of Africa, Asia and Southern Europe. Vaccination is critical for the control of this disease but only live attenuated vaccines are currently available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!